Wolverine Trading
CCCC icon

Wolverine Trading’s C4 Therapeutics CCCC Stock Holding History

Wolverine Trading’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$28.3K Buy
+12,710
New +$30.5K ﹤0.01% 5506

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wolverine Trading's CCCC Position: Q3 2025 in Review

Wolverine Trading opened a new position in C4 Therapeutics (CCCC) in Q3 2025: 12,710 shares worth $28.3K. The stake represents ﹤0.01% of the portfolio and ranks #5506 among its holdings.

97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Wolverine Trading held 12,710 shares of C4 Therapeutics worth $28.3K as of Q3 2025.
  • C4 Therapeutics was a new Wolverine Trading position in Q3 2025.
  • C4 Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5506 holding.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.